Profile data is unavailable for this security.
About the company
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
- Revenue in USD (TTM)0.00
- Net income in USD-148.97m
- Incorporated2013
- Employees95.00
- LocationSpyre Therapeutics Inc221 Crescent Street, Suite 105WALTHAM 02453United StatesUSA
- Phone+1 (617) 651-5940
- Fax+1 (302) 636-5454
- Websitehttps://spyre.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunome Inc | 9.68m | -222.74m | 2.44bn | 118.00 | -- | 7.70 | -- | 252.60 | -2.95 | -2.95 | 0.122 | 2.88 | 0.0348 | -- | -- | 82,025.42 | -80.08 | -120.50 | -91.80 | -146.20 | -- | -- | -2,301.30 | -2,078.20 | -- | -- | 0.00 | -- | -35.50 | -- | -174.29 | -- | 196.63 | -- |
| Adaptive Biotechnologies Corp | 276.98m | -59.50m | 2.47bn | 619.00 | -- | 11.27 | -- | 8.91 | -0.3987 | -0.3987 | 1.79 | 1.42 | 0.5265 | 7.82 | 6.01 | -- | -11.30 | -22.45 | -13.86 | -25.94 | 74.24 | 66.23 | -21.47 | -88.21 | 3.23 | -24.47 | 0.3684 | -- | 54.77 | 23.00 | 62.69 | -- | -- | -- |
| Travere Therapeutics Inc | 435.83m | -88.54m | 2.49bn | 385.00 | -- | 33.83 | -- | 5.71 | -1.08 | -1.08 | 4.80 | 0.8223 | 0.8357 | 1.74 | 8.06 | 1,132,018.00 | -16.98 | -41.64 | -24.67 | -51.97 | 97.63 | 95.90 | -20.32 | -175.36 | 2.71 | -- | 0.8089 | -- | 60.55 | 5.87 | 14.80 | -- | 45.42 | -- |
| Dyne Therapeutics Inc | 0.00 | -423.80m | 2.51bn | 240.00 | -- | 3.20 | -- | -- | -3.66 | -3.66 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -51.81 | -57.98 | -55.30 | -63.58 | -- | -- | -- | -- | -- | -- | 0.1254 | -- | -- | -- | -34.54 | -- | 7.60 | -- |
| Ideaya Biosciences Inc | 214.83m | -160.74m | 2.65bn | 131.00 | -- | 2.43 | -- | 12.35 | -1.85 | -1.85 | 2.43 | 12.46 | 0.1772 | -- | -- | 1,639,954.00 | -13.26 | -22.71 | -13.86 | -24.48 | -- | -- | -74.82 | -411.78 | -- | -- | 0.00 | -- | -70.07 | -- | -142.98 | -- | 23.31 | -- |
| Viridian Therapeutics Inc | 70.79m | -301.97m | 2.66bn | 143.00 | -- | 7.30 | -- | 37.62 | -3.72 | -3.72 | 0.8716 | 6.12 | 0.105 | -- | 2.02 | 495,028.00 | -44.77 | -50.26 | -48.05 | -53.97 | -- | -- | -426.58 | -12,930.56 | -- | -- | 0.0399 | -- | -3.82 | -41.64 | -13.55 | -- | 43.49 | -- |
| Veracyte Inc | 495.14m | 30.32m | 2.83bn | 824.00 | 94.36 | 2.25 | 53.67 | 5.71 | 0.3791 | 0.3791 | 6.21 | 15.91 | 0.3747 | 7.66 | 10.25 | 600,899.30 | 2.29 | -4.19 | 2.43 | -4.43 | 68.53 | 66.82 | 6.12 | -13.70 | 5.94 | -- | 0.00 | -- | 23.46 | 29.93 | 132.44 | -- | 32.57 | -- |
| Beam Therapeutics Inc | 55.70m | -414.64m | 2.83bn | 483.00 | -- | 2.93 | -- | 50.86 | -4.43 | -4.43 | 0.5936 | 9.53 | 0.0449 | -- | -- | 115,323.00 | -33.41 | -24.98 | -38.87 | -29.69 | -- | -- | -744.41 | -241.53 | -- | -- | 0.00 | -- | -83.18 | 412.30 | -184.28 | -- | -6.50 | -- |
| Spyre Therapeutics Inc | 0.00 | -148.97m | 2.84bn | 95.00 | -- | 7.40 | -- | -- | -2.55 | -2.55 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -32.19 | -75.44 | -36.25 | -85.33 | -- | -- | -- | -3,540.66 | -- | -- | 0.00 | -- | -100.00 | -- | 38.60 | -- | -- | -- |
| Denali Therapeutics Inc | 0.00 | -498.74m | 2.92bn | 517.00 | -- | 2.97 | -- | -- | -2.91 | -2.91 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -39.75 | -16.91 | -42.77 | -19.81 | -- | -- | -- | -135.24 | -- | -- | 0.006 | -- | -100.00 | -- | -191.12 | -- | -2.35 | -- |
| Vera Therapeutics Inc | 0.00 | -251.94m | 2.96bn | 224.00 | -- | 6.76 | -- | -- | -3.98 | -3.98 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -56.87 | -54.55 | -61.62 | -60.06 | -- | -- | -- | -- | -- | -- | 0.1576 | -- | -- | -- | -58.50 | -- | 50.71 | -- |
| Edgewise Therapeutics Inc | 0.00 | -157.24m | 3.18bn | 136.00 | -- | 5.68 | -- | -- | -1.58 | -1.58 | 0.00 | 5.28 | 0.00 | -- | -- | 0.00 | -28.73 | -26.21 | -29.83 | -27.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.60 | -- | 48.78 | -- |
| Xenon Pharmaceuticals Inc | 7.50m | -306.33m | 3.21bn | 316.00 | -- | 5.72 | -- | 427.38 | -3.88 | -3.88 | 0.0952 | 7.26 | 0.0104 | -- | 8.57 | 23,734.18 | -42.44 | -22.00 | -44.53 | -22.93 | -- | -- | -4,084.45 | -1,082.36 | -- | -- | 0.00 | -- | -- | -- | -28.48 | -- | 19.92 | -- |
| Legend Biotech Corp (ADR) | 908.96m | -239.70m | 3.25bn | 2.90k | -- | 3.21 | -- | 3.57 | -1.30 | -1.30 | 4.94 | 5.48 | 0.5271 | 13.60 | 936.59 | 349,601.20 | -13.90 | -30.18 | -17.47 | -36.54 | 60.55 | -- | -26.37 | -154.41 | 2.80 | -1.36 | 0.2886 | -- | 119.97 | 59.91 | 65.84 | -- | -18.48 | -- |
| Alumis Inc | 22.12m | -245.15m | 3.31bn | 233.00 | -- | 7.20 | -- | 149.56 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.35bn | 53.00 | -- | 5.21 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Spyre Therapeutics Inc's reporting currency: US Dollar USD
49.88%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 8.97m | 11.56% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.99m | 6.44% |
| Fairmount Funds Management LLCas of 15 Oct 2025 | 4.02m | 5.18% |
| RTW Investments LPas of 30 Sep 2025 | 3.62m | 4.67% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.50m | 4.51% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2025 | 3.49m | 4.50% |
| Tang Capital Management LLCas of 30 Sep 2025 | 3.20m | 4.12% |
| Braidwell LPas of 30 Sep 2025 | 2.58m | 3.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.26m | 2.92% |
| Driehaus Capital Management LLCas of 30 Sep 2025 | 2.06m | 2.66% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
